ScreenerHero

TYRA Tyra Biosciences, Inc.

NAS · US · Healthcare · Biotechnology · tyra.bio
20.39USD+0.74%Mkt Cap: 1.40B $P/E: —

Tyra Biosciences, Inc., a clinical-stage biotechnology company, develops precision medicines for fibroblast growth factor receptor (FGFR) biology in the United States. The company offers SNÅP, a precision medicine platfo…

Industry Peers

Biotechnology
Screen all
VRTX
Vertex Pharmaceuticals Incorporated
$128.08BUSDP/E 29.4
MRNA
Moderna, Inc.
$78.44BUSD
REGN
Regeneron Pharmaceuticals, Inc.
$76.40BUSDP/E 18.4
ARGX
argenx SE
$57.03BUSDP/E 37.3
ARGX
argenx SE
$58.08BUSDP/E 35.4
UCB
UCB SA
$42.24BUSDP/E 18.0
RVMD
Revolution Medicines, Inc.
$43.05BUSD
ONC
BeOne Medicines AG
$41.41BUSDP/E 65.1
RPRX
Royalty Pharma plc
$32.80BUSDP/E 30.2
ALNY
Alnylam Pharmaceuticals, Inc.
$30.03BUSDP/E 37.8
ROIV
Roivant Sciences Ltd.
$25.10BUSD
BNTX
BioNTech SE
$23.93BUSD
INCY
Incyte Corporation
$22.99BUSDP/E 14.5
GMAB
Genmab A/S
$22.27BUSDP/E 30.7
GMAB
Genmab A/S
$22.54BUSDP/E 28.9
INSM
Insmed Incorporated
$22.22BUSD
ASND
Ascendis Pharma A/S
$15.03BUSDP/E 17.5
JAZZ
Jazz Pharmaceuticals plc
$15.01BUSDP/E 15.8
EXEL
Exelixis, Inc.
$14.48BUSDP/E 18.4
SMMT
Summit Therapeutics Inc.
$14.32BUSD

Key Statistics

Company
Market Cap1.40B USD
Enterprise Value859.50M USD
Revenue (TTM)—
Gross Profit—
Net Income (TTM)-119.95M USD
Revenue/Share—
Last Price20.39 USD
Fiscal Year EndDec 2025
MR QuarterJun 2026
Employees87
CountryUS
SectorHealthcare
IndustryBiotechnology
ISIN—
Valuation
P/E (Trailing)—
P/E (Forward)-7.31
PEG—
EV/EBITDA-5.37
EV/Revenue—
P/S—
P/B3.41
EPS (TTM)-2.32
EPS (Forward)-2.77
52W Range
12.4028% of range40.65
52W High40.65 USD
52W Low12.40 USD
Profitability
Gross Margin0.00%
Oper. Margin0.00%
EBITDA Margin0.00%
Profit Margin0.00%
ROE-46.28%
ROA-42.44%
Growth
Revenue Growth—
Earnings Growth—
Cash Flow & Leverage
Operating CF-95.14M USD
CapEx (TTM)141.00K USD
FCF Margin—
FCF Yield-4.50%
Net Debt-348.36M USD
Net Debt/EBITDA2.18
Balance Sheet
Debt/Equity0.02
Current Ratio14.90
Quick Ratio14.48
Book Value/Sh5.93 USD
Cash/Share5.93 USD
Dividends
Fwd Div Rate—
Trail. Div Rate0.00 USD
Div. Yield0.00%
5Y Avg Yield—
Payout Ratio0.00%
Ex-Div Date—
Pay Date—
Analyst Consensus
Rating1.3 (Strong Buy)
Strong BuyBuyHoldSellStr. Sell
Target (Mean)47.45 USD
Upside (mean)+132.7%
Target Range29.00 USD – 59.00 USD
29.00+132.7% to mean59.00
# Analysts11
Ownership
Shares Out.68.76M
Float34.65M
Insiders2.43%
Institutions108.25%
Short Interest
Short Ratio9.5d
Short % Float23.82%
Short % Out.14.37%
Shares Short9.88M
Short (prev mo.)9.69M
Technical
SMA 5025.68 (-20.6%)
SMA 20030.50 (-33.1%)
Beta0.75
S&P 52W Chg16.45%
Avg Vol (30d)1.09M
Avg Vol (10d)974.17K
Technical Indicators
RSI (14)36.7
MACD-1.6011
MACD Signal-1.4579
MACD Hist.-0.1431
BB Upper27.80 USD
BB Middle23.02 USD
BB Lower18.25 USD
BB Width41.46%
ATR (14)1.638 USD
Vol Ratio (20d)0.33x